September 17, 2010
Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.
Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action
Released on September 17
Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical, Head Office: Tokyo, Japan, President and Representative Director: Taro Iwamoto) and UCB Japan Co. Ltd. (UCB Japan, Head Office: Tokyo, Japan, President and Representative Director: Emmanuel Caeymaex) (solely "UCB" refers to the whole UCB group) today announced the launch of the antiepileptic drug 'E Keppra®' (nonproprietary name: levetiracetam) 250mg and 500mg tablets, which have completely different mechanism of action from those of conventional medications, on September 17.
Information in this news release was current as of the original release date.